Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster

Cytokine. 2022 Aug:156:155917. doi: 10.1016/j.cyto.2022.155917. Epub 2022 May 31.

Abstract

Gastrointestinal (GI) cancers refer to a group of malignancies associated with the GI tract (GIT). Like other solid tumors, hypoxic regions consistently feature inside the GI tumor microenvironment (TME) and contribute towards metabolic reprogramming of tumor-resident cells by modulating hypoxia-induced factors. We highlight here how the metabolic crosstalk between cancer cells and immune cells generate immunosuppressive environment inside hypoxic tumors. Given the fluctuating nature of tumor hypoxia, the metabolic fluxes between immune cells and cancer cells change dynamically. These changes alter cellular phenotypes and functions, resulting in the acceleration of cancer progression. These evolved properties of hypoxic tumors make metabolism-targeting monotherapy approaches or immunotherapy-measures unsuccessful. The current review highlights the advantages of combined immunometabolic treatment strategies to target hypoxic GI cancers and also identifies research areas to develop better combinational therapeutics for future.

Keywords: Gastrointestinal cancer; Hypoxia; Immunometabolic therapy; Immunotherapy; Metabolism; Tumor heterogeneity; Tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disasters*
  • Gastrointestinal Neoplasms* / therapy
  • Humans
  • Hypoxia
  • Immunotherapy / methods
  • Neoplasms* / metabolism
  • Tumor Microenvironment